STOCK TITAN

Cocrystal Pharma, Inc. - COCP STOCK NEWS

Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.

Cocrystal Pharma, Inc. (symbol: COCP) is an innovative pharmaceutical company dedicated to discovering and developing novel antiviral therapeutics. With a primary focus on treating serious and chronic viral diseases, Cocrystal employs advanced technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. By leveraging unique nucleoside chemistry and a market-focused approach to drug discovery, the company aims to deliver small molecule therapeutics that are safe, effective, and convenient to administer.

The company has made significant strides in identifying promising preclinical stage antiviral compounds that address unmet medical needs. These include treatments for hepatitis, influenza, and norovirus infections. Among its notable projects, Cocrystal Pharma is developing CC-31244, an oral, broad-spectrum replication inhibitor known as a non-nucleoside inhibitor (NNI). This investigational drug targets the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses, showcasing the company's commitment to creating groundbreaking antiviral solutions.

Cocrystal Pharma has garnered strategic investments from major industry players such as Teva Pharmaceuticals, Opko Health (OPK), Dr. Raymond Schinazi, Brace Pharmaceutical, LLC, and The Frost Group. This backing underscores the confidence that leading pharmaceutical entities have in Cocrystal's potential and technological capabilities.

As Cocrystal Pharma continues to advance its pipeline of antiviral therapeutics, the company's innovative approach and robust partnerships position it as a significant player in the biotechnology sector. Investors and stakeholders can stay updated on the latest developments, financial reports, and strategic initiatives that propel Cocrystal Pharma forward in its mission to combat viral diseases.

For those interested in the latest updates and relevant information regarding Cocrystal Pharma and its stock performance, be sure to check the latest news and announcements below.

  • ---
  • ---
  • ---
  • ---
  • ---
  • ---
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that President and co-interim CEO Sam Lee, PhD, will present a company overview focusing on antiviral programs and clinical trials at the LD Micro Main Event XV. The presentation is scheduled for October 26, 2022, at 3:30 p.m. Pacific time (6:30 p.m. Eastern time) at the Luxe Sunset Boulevard Hotel, Los Angeles. Interested parties can access the live webcast and archived presentation on the IR Calendar of the company website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
conferences
-
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) will present data from its Phase 1 clinical trial of CC-42344, a novel antiviral targeting influenza A, at the upcoming World Antiviral Congress on December 1, 2022. Dr. Sam Lee, co-interim CEO, expressed excitement about sharing this first-in-human trial data, which aims to address both seasonal and pandemic influenza. The company plans to initiate a Phase 2a human challenge trial, leveraging advanced antiviral technology with a promising safety profile. The global influenza therapeutics market is expected to grow, reaching $9.5 billion by 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
conferences clinical trial
-
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) has chosen its antiviral drug candidate CDI-988 for clinical development as an oral treatment for COVID-19. This candidate targets a key region in the SARS-CoV-2 main protease, showcasing superior in vitro potency compared to competitors. With favorable safety and pharmacokinetic profiles, CDI-988 is positioned for a first-in-human trial in Australia anticipated in Q1 2023, following IND-enabling toxicology studies. Cocrystal aims to advance antiviral therapeutics to combat various viral diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.42%
Tags
clinical trial covid-19
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) has announced that James Martin, CFO and interim co-CEO, will present a company overview at the Dawson James Securities 2022 Small Cap Growth Conference on October 12, 2022, at 1:00 p.m. Eastern time. The event is scheduled at the Wyndham Grand Hotel in Jupiter, Florida. Mr. Martin will also be available for one-on-one meetings throughout the conference. The presentation will be accessible on the company's website starting October 12.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced a 1-for-12 reverse stock split approved by its Board of Directors, effective October 11, 2022. This move aims to maintain compliance with Nasdaq Rule 5550(a)(2), which requires share prices to be above $1.00 for 30 consecutive trading days to avoid delisting. Following the split, the outstanding shares will decrease from approximately 97.5 million to around 8.1 million, while the authorized shares remain at 150 million. No fractional shares will be issued, and existing equity awards will be proportionately adjusted.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.33%
Tags
none
-
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, via a hybrid model. James Martin, CFO and interim co-CEO, will present on-demand starting September 12 at 7:00 a.m. ET. Attendees can engage in virtual one-on-one meetings throughout the conference. Interested investors and industry professionals can register for attendance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
conferences
Rhea-AI Summary

Cocrystal Pharma (Nasdaq: COCP) reported its Q2 2022 financial results and updates on antiviral pipeline developments. The company is advancing its oral PB2 inhibitor CC-42344, with a Phase 2a study planned to evaluate its efficacy against influenza A. Recent pharmacokinetic data supports once-daily dosing for CC-42344. Collaboration with NIAID is ongoing for COVID-19 protease inhibitors, with plans for two Phase 1 studies this year. Financially, Cocrystal faced a net loss of $24.4 million in Q2, including a $19.1 million non-cash goodwill impairment due to stock price decreases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
-
Rhea-AI Summary

Cocrystal Pharma (Nasdaq: COCP) has completed the single ascending dose portion of its Phase 1 study for the antiviral candidate CC-42344, showing favorable pharmacokinetic data that supports once-daily dosing potential. The study, conducted in Australia, aims to assess safety and tolerability in healthy adults. Preliminary data indicated a positive safety profile for doses of 100 mg and 200 mg. CC-42344 acts as a PB2 inhibitor and demonstrates antiviral activity against resistant influenza A strains, potentially outperforming existing treatments like Tamiflu.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) has entered into a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases (NIAID) for preclinical studies on its 3CL protease inhibitors for COVID-19 treatment. This collaboration will support the scale-up synthesis of a key intermediate necessary for the development of these inhibitors. Cocrystal aims to create antiviral drugs targeting viral replication proteins, potentially beneficial against various coronaviruses, including COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
covid-19
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) has announced that James Martin, Chief Financial Officer and co-interim CEO, will present a company overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 10:00 a.m. Eastern Time. This hybrid event will take place at the Fontainebleau Miami Beach Hotel. A live webcast of the presentation will be available on the company’s IR Calendar and archived for 90 days.

Cocrystal specializes in developing antiviral therapeutics targeting influenza, coronaviruses, and more.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the current stock price of Cocrystal Pharma (COCP)?

The current stock price of Cocrystal Pharma (COCP) is $2.15 as of November 21, 2024.

What is the market cap of Cocrystal Pharma (COCP)?

The market cap of Cocrystal Pharma (COCP) is approximately 22.1M.

What does Cocrystal Pharma, Inc. do?

Cocrystal Pharma, Inc. is a pharmaceutical company focused on discovering and developing novel antiviral therapeutics for serious and chronic viral diseases.

What are Cocrystal Pharma's key areas of focus?

The company focuses on creating antiviral treatments for hepatitis, influenza, and norovirus infections.

What is CC-31244?

CC-31244 is an investigational, oral, broad-spectrum replication inhibitor developed by Cocrystal Pharma to target the replication machinery of influenza, hepatitis C, and noroviruses.

What technologies does Cocrystal employ?

Cocrystal uses advanced structure-based technologies and nucleoside chemistry to create first-in-class antiviral drugs, backed by Nobel Prize-winning expertise.

Who are some of Cocrystal Pharma's strategic investors?

Notable investors include Teva Pharmaceuticals, Opko Health, Dr. Raymond Schinazi, Brace Pharmaceutical, LLC, and The Frost Group.

How does Cocrystal's drug discovery approach differ from others?

Cocrystal's approach is market-focused and uses innovative nucleoside chemistry to efficiently deliver safe, effective, and convenient small molecule therapeutics.

What stage are Cocrystal's antiviral compounds in?

Cocrystal has identified promising preclinical stage antiviral compounds for various unmet medical needs.

What makes Cocrystal Pharma unique?

Cocrystal's unique blend of advanced technologies, Nobel Prize-winning expertise, and strong industry partnerships sets it apart in the biotechnology field.

Where can I find the latest news on Cocrystal Pharma?

Latest updates and relevant information about Cocrystal Pharma can be found on the StockTitan website, under the COCP stock section.

What is the main goal of Cocrystal Pharma?

The main goal of Cocrystal Pharma is to develop innovative antiviral therapeutics that effectively treat serious and chronic viral diseases.

Cocrystal Pharma, Inc.

Nasdaq:COCP

COCP Rankings

COCP Stock Data

22.05M
6.93M
31.85%
6.94%
0.02%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOTHELL